litifilimab
Sponsor Biogen INC. · listed as BIIB
litifilimab is a drug asset sponsored by Biogen INC., listed as BIIB. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Oct 20, 2026 (day precision, medium confidence), tied to trial NCT05531565. That trial is in Phase 2/3 and currently active not recruiting, studying Subacute Cutaneous Lupus Erythematosus. It appears across 5 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for litifilimab in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT04961567 | Phase 3 | Active, not recruiting | 2026-09-27 | Experimental | Biogen | Lupus Erythematosus, Systemic |
| NCT04895241 | Phase 3 | Active, not recruiting | 2026-09-30 | Experimental | Biogen | Lupus Erythematosus, Systemic |
| NCT05531565 catalyst | Phase 2/3 | Active, not recruiting | 2026-10-20 | Experimental | Biogen | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus |
| NCT06044337 | Phase 3 | Enrolling by invitation | 2029-06-26 | Experimental | Biogen | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus |
| NCT05352919 | Phase 3 | Enrolling by invitation | 2032-05-03 | Experimental | Biogen | Systemic Lupus Erythematosus (SLE) |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More BIIB catalysts